Wart Remover

Description

The product is identified by the SPL code 34089-3. No specific description details are provided in the text.

Uses and Indications

This drug is indicated for the removal of common warts, which are characterized by their rough, 'cauliflower-like' surface appearance. Additionally, it is indicated for the removal of plantar warts, which are specifically located on the bottom of the foot and are identified by tenderness and disruption of the footprint pattern.

Limitations of Use: This drug is not indicated for the treatment of warts located on the face, genitals, or mucous membranes.

Dosage and Administration

For the removal of common and plantar warts, the affected area should first be washed thoroughly. It is recommended to soak the wart in warm water for approximately 5 minutes to facilitate the treatment process. After soaking, the area must be dried thoroughly to ensure proper adhesion of the medicated plaster.

The medicated plaster should be cut to fit the size of the wart accurately. Once prepared, the plaster should be applied directly to the wart. This procedure may be repeated every 48 hours as necessary, continuing until the wart is removed, with a maximum treatment duration of up to 12 weeks.

Contraindications

There are no specific contraindications listed for this product. However, it is essential to keep the product out of reach of children to prevent accidental ingestion or misuse.

Warnings and Precautions

This product is intended for external use only. It is imperative that healthcare professionals advise patients against applying this product to any areas of the skin that are irritated, infected, or reddened. Special caution should be exercised in patients with diabetes or those who exhibit poor blood circulation, as these conditions may exacerbate potential adverse effects.

In the event that discomfort persists following application, patients should be instructed to seek medical advice promptly. Additionally, this product must not be used on moles, birthmarks, or warts that have hair growing from them. It is also contraindicated for use on genital warts or warts located on the face or mucous membranes.

Healthcare professionals should ensure that patients are fully informed of these warnings and precautions to promote safe and effective use of the product.

Side Effects

Patients should be aware that this product is for external use only. It is contraindicated for use on irritated skin, infected or reddened areas, and should not be applied if the patient is diabetic or has poor blood circulation.

In the event that discomfort persists after application, patients are advised to consult their healthcare provider. Additionally, the product should not be used on moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes.

Drug Interactions

There are no reported drug interactions associated with the use of this medication. Additionally, no interactions with laboratory tests have been identified. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Wart Remover (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. There are no specific age ranges, dosage differences, or study outcomes provided for pediatric use in the available data. Caution is advised when administering this medication to ensure safety in the pediatric population.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

The safety of this product during pregnancy has not been established. This product is contraindicated in pregnancy due to potential risks to the fetus. Healthcare professionals should advise pregnant patients to avoid the use of this product to mitigate any potential adverse fetal outcomes. Women of childbearing potential should be informed of these risks and counseled on appropriate contraceptive measures while using this product.

Lactation

There are no specific warnings or considerations regarding the use of this product in lactating mothers. Additionally, there is no information available about the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs.

If available, specific antidotes or treatments should be administered as indicated based on the substance involved. Consultation with a poison control center or a medical toxicologist may be beneficial for guidance on management strategies tailored to the specific situation.

Documentation of the incident, including the amount and timing of the substance taken, is crucial for effective management and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question. Further studies may be necessary to elucidate these aspects of nonclinical toxicology.

Postmarketing Experience

No postmarketing experience details are provided in the insert.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children to prevent accidental ingestion or misuse. It is important for patients to understand the potential risks associated with improper access to the medication by young individuals. Providers should emphasize the necessity of storing the medication in a secure location, away from children's sight and reach, to ensure safety.

Storage and Handling

The product is supplied in a configuration that ensures optimal usability. It should be stored at room temperature, specifically in a cool, dry place to maintain its integrity. It is essential to protect the product from moisture and to avoid freezing, as these conditions may compromise its effectiveness.

Additionally, the product must be kept out of reach of children to ensure safety. Once opened, any unused portion should be discarded to prevent potential contamination or degradation.

Additional Clinical Information

The medication is administered topically, with the procedure to be repeated every 48 hours as needed until the wart is removed, for a maximum duration of 12 weeks. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)